Introducing the Most Advanced Alternative to Thorough QT Studies
Please join Daniel Goodman, MD, Vice President and Medical Director at BioTelemetry Research for a complimentary webinar on EvriBeat – Dynamic Electrocardiography. This webinar will guide you through BioTelemetry Research’s exclusive offering, EvriBeat, an advanced method for assessing cardiac safety in early human trials. EvriBeat provides a powerful and efficient alternative to Thorough QT studies and it is ideal for SAD/MAD protocols, providing definitive QTc data earlier and more affordably than other methods.
Key topics will include:
- Continuous recording and analysis features
- Complete, continuous 24-hour Holter data, beat-to-beat QT and RR data
- Concentration-Regression analysis features
- Additional procedures available on-demand and much more!
Join us to learn how you can potentially collect your QTc data earlier while also reducing costs with EvriBeat – Dynamic Electrocardiography.
Daniel B. Goodman, MD, Vice President and Medical Director, BioTelemetry Research
Dr. Goodman directs all aspects of protocol planning and development for Sponsors, and for analysis of cardiac safety results. He is materially involved in innovations in medical technology and novel analyses, as well as in implementing the latest regulatory initiatives. He has direct interactions with key sponsor personnel and with academic experts to provide expert consulting solutions. Dr. Goodman received his training at Yale University and Cornell University Medical School. In the early 1990s, he founded Cardiology for Clinical Trials, one of the world’s first cardiac core labs. Dr. Goodman went on to direct medical affairs for Covance Cardiac Safety Services from 1994 until 2007. After this post, Dr. Goodman worked closely with the medical team as a senior scientific consultant for several years, while practicing medicine intermittently. Dr. Goodman is an international thought leader in cardiac safety testing, developing protocols, producing scientific reports, conferring with regulators and publishing extensively.
Who Should Attend?
This webinar will benefit professionals within biopharmaceutical research and medical device organizations, specifically those in the following roles:
- Chief Medical Officer
- VP Clinical Operations
- VP Clinical Development
- Director Clinical Operations
- Director Clinical Development
- Clinical Pharmacologist
- Director, Clinical Pharmacology Unit, Phase I
- Medical Director, Phase I
- Medical Writers
As the research division of BioTelemetry Inc. (Nasdaq: BEAT), BioTelemetry Research, formerly Cardiocore, provides one of the world’s largest clinical data networks. Our broad range of Cardiac and Imaging services support both safety assessments and efficacy evaluations across all major therapeutic areas, through all phases of clinical trials, in every global region.
BioTelemetry Research offers a full range of centralized clinical trial testing modalities for both safety and endpoint evaluation. Cardiac includes ECG, Holter, TTM, MCOT, ECHO, and ABPM/BP. BioTelemetry Research provides Imaging services across therapeutic areas, including Oncology, CNS, Musculoskeletal, and Cardiovascular. Supported Imaging modalities include MRI, X-Ray, PET/CT, Bone Scintigraphy, and others.